

Clinical Policy: Lomitapide (Juxtapid)

Reference Number: IL.ERX.SPA.170

Effective Date: 06.01.21

Last Review Date: 05.21

Line of Business: Illinois Medicaid

[Revision Log](#)

See **Important Reminder** at the end of this policy for important regulatory and legal information.

Description

Lomitapide (Juxtapid[®]) is a microsomal triglyceride transfer protein inhibitor.

FDA Approved Indication(s)

Juxtapid is indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein (LDL) apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

Limitation(s) of use:

- The safety and effectiveness of Juxtapid have not been established in patients with hypercholesterolemia who do not have HoFH, including those with heterozygous familial hypercholesterolemia (HeFH).
- The effect of Juxtapid on cardiovascular morbidity and mortality has not been determined.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary.

It is the policy of health plans affiliated with Envolve Pharmacy Solutions[™] that Juxtapid is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Homozygous Familial Hypercholesterolemia (must meet all):

1. Diagnosis of HoFH defined as one of the following (a, b, or c):
 - a. Genetic mutation indicating HoFH (e.g., mutations in low density lipoprotein receptor [LDLR] gene, proprotein convertase subtilisin kexin 9 [PCSK9] gene, apo B gene, low density lipoprotein receptor adaptor protein 1 [LDLRAP1] gene);
 - b. Treated LDL-C \geq 300 mg/dL or non-HDL-C \geq 330 mg/dL;
 - c. Untreated LDL-C \geq 500 mg/dL, and one of the following (i or ii):
 - i. Tendinous or cutaneous xanthoma prior to age 10 years;
 - ii. Evidence of HeFH in both parents (e.g., documented history of elevated LDL-C \geq 190 mg/dL prior to lipid-lowering therapy);
2. Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist;
3. Age \geq 18 years;
4. Documentation of recent (within the last 60 days) LDL-C \geq 70 mg/dL;
5. For members on statin therapy, both of the following (a and b):
 - a. Juxtapid is prescribed in conjunction with a statin at the maximally tolerated dose;
 - b. Member has been adherent for at least the last 4 months to maximally tolerated doses of one of the following statin regimens (i, ii, or iii):
 - i. A high intensity statin (see Appendix D);
 - ii. A moderate intensity statin (see Appendix D), and member has one of the following (a or b):

- a) Intolerance to two high intensity statins;
- b) A statin risk factor (see Appendix F);
- iii. A low intensity statin, and member has one of the following (a or b):
 - a) Intolerance to one high and one moderate intensity statins;
 - b) A statin risk factor (see Appendix F) and history of intolerance to two moderate intensity statins;
6. For members not on statin therapy, member meets one of the following (a or b):
 - a. Statin therapy is contraindicated per Appendix E;
 - b. For members who are statin intolerant, member has tried at least two statins, one of which must be hydrophilic (pravastatin, fluvastatin, or rosuvastatin), and member meets one of the following (i or ii):
 - i. Member has documented statin risk factors (see Appendix F);
 - ii. Member is statin intolerant due to statin-associated muscle symptoms (SAMS) and meets both of the following (a and b):
 - a) Documentation of intolerable SAMS persisting at least two weeks, which disappeared with discontinuing the statin therapy and recurred with a statin re-challenge;
 - b) Documentation of re-challenge with titration from lowest possible dose and/or intermittent dosing frequency (e.g., 1 to 3 times weekly);
7. Member has been adherent to ezetimibe therapy used concomitantly with a statin at the maximally tolerated dose for at least the last 4 months, unless contraindicated per Appendix E or member has a history of ezetimibe intolerance (e.g., associated diarrhea or upper respiratory tract infection);
8. Treatment plan does not include coadministration with Kynamro®, Repatha, or Praluent®;
9. Dose does not exceed 60 mg (one capsule) per day.

Approval duration: 6 months

B. Other diagnoses/indications

1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

II. Continued Therapy

A. Homozygous Familial Hypercholesterolemia (must meet all):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria;
2. If statin tolerant, documentation of adherence to a statin at the maximally tolerated dose;
3. Member is responding positively to therapy as evidenced by lab results within the last 3 months showing an LDL-C reduction since initiation of Juxtapid therapy;
4. If request is for a dose increase, new does not exceed 60 mg (one capsule) per day.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.

Approval duration: Duration of request or 6 months (whichever is less); or

2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

III. Diagnoses/Indications for which coverage is NOT authorized:

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

ALT: alanine aminotransferase

apoB: apolipoprotein B

FDA: Food and Drug Administration
 HDL-C: high-density lipoprotein cholesterol
 HeFH: heterozygous familial hypercholesterolemia
 HoFH: homozygous familial hypercholesterolemia
 LDL-C: low density lipoprotein cholesterol

LDLR: low density lipoprotein receptor
 LDLRAP1: low density lipoprotein receptor adaptor protein 1
 PCSK9: proprotein convertase subtilisin kexin 9
 SAMS: statin-associated muscle symptoms
 TC: total cholesterol
 ULN: upper limit of normal

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
ezetimibe/simvastatin (Vytorin [®])	10/40 mg PO QD	10 mg-40 mg/day (use of the 10/80 mg dose is restricted to patients who have been taking simvastatin 80 mg for ≥ 12 months without evidence of muscle toxicity)
ezetimibe (Zetia [®])	10 mg PO QD	10 mg/day
atorvastatin (Lipitor [®])	40 mg PO QD	80 mg/day
rosuvastatin (Crestor [®])	5 - 40 mg PO QD	40 mg/day

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s):
 - Pregnancy
 - Concomitant use with strong or moderate CYP3A4 inhibitors
 - Moderate or severe hepatic impairment (Child-Pugh B or C) or active liver disease, including unexplained persistent elevations of serum transaminases
- Boxed warning(s): risk of hepatotoxicity

Appendix D: High and Moderate Intensity Daily Statin Therapy for Adults

<p>High Intensity Statin Therapy <i>Daily dose shown to lower LDL-C, on average, by approximately ≥ 50%</i></p> <ul style="list-style-type: none"> • Atorvastatin 40-80 mg • Rosuvastatin 20-40 mg
<p>Moderate Intensity Statin Therapy <i>Daily dose shown to lower LDL-C, on average, by approximately 30% to 50%</i></p> <ul style="list-style-type: none"> • Atorvastatin 10-20 mg • Fluvastatin XL 80 mg • Fluvastatin 40 mg BID • Lovastatin 40 mg • Pitavastatin 1-4 mg • Pravastatin 40-80 mg • Rosuvastatin 5-10 mg • Simvastatin 20-40 mg
<p>Low Intensity Statin Therapy <i>Daily dose shown to lower LDL-C, on average, by < 30%</i></p> <ul style="list-style-type: none"> • Simvastatin 10 mg • Pravastatin 10-20 mg • Lovastatin 20 mg • Fluvastatin 20-40 mg

Appendix E: Statin and Ezetimibe Contraindications

Statin
<ul style="list-style-type: none"> Decompensated liver disease (development of jaundice, ascites, variceal bleeding, encephalopathy) Laboratory-confirmed acute liver injury or rhabdomyolysis resulting from statin treatment Pregnancy, actively trying to become pregnant, or nursing Immune-mediated hypersensitivity to the HMG-CoA reductase inhibitor drug class (statins) as evidenced by an allergic reaction occurring with at least TWO different statins
Ezetimibe
<ul style="list-style-type: none"> Moderate or severe hepatic impairment [Child-Pugh classes B and C] Hypersensitivity to ezetimibe (e.g., anaphylaxis, angioedema, rash, urticaria)

Appendix F: Statin Risk Factors

Statin Risk Factors
<ul style="list-style-type: none"> Multiple or serious comorbidities, including impaired renal or hepatic function Unexplained alanine transaminase (ALT) elevations > 3 times upper limit of normal, or active liver disease Concomitant use of drugs adversely affecting statin metabolism Age > 75 years, or history of hemorrhagic stroke Asian ancestry

Appendix G: General Information

- Because of the risk of hepatotoxicity, Juxtapid is available only through a Risk Evaluation and Mitigation Strategy (REMS) program called the Juxtapid REMS Program.
- Low density lipoprotein receptor adaptor protein 1 (LDLRAP1) gene is also known as autosomal recessive hypercholesterolemia (ARH) adaptor protein 1 gene.
- The diagnosis of SAMS is often on the basis of clinical criteria. Typical SAMS include muscle pain and aching (myalgia), cramps, and weakness. Symptoms are usually bilateral and involve large muscle groups, including the thigh, buttock, back, and shoulder girdle musculature. In contrast, cramping is usually unilateral and may involve small muscles of the hands and feet. Symptoms may be more frequent in physically active patients. Symptoms often appear early after starting statin therapy or after an increase in dose and usually resolve or start to dissipate within weeks after cessation of therapy, although it may take several months for symptoms to totally resolve. Persistence of symptoms for more than 2 months after drug cessation should prompt a search for other causes or for underlying muscle disease possibly provoked by statin therapy. The reappearance of symptoms with statin rechallenge and their disappearance with drug cessation offers the best evidence that the symptoms are truly SAMS.
- Pravastatin, fluvastatin, and rosuvastatin are hydrophilic statins which have been reported to confer fewer adverse drug reactions than lipophilic statins.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
HoFH	5 mg PO QD up to maximum dose following a specific titration schedule as follows (dose: duration of administration before considering increase to next dosage): <ul style="list-style-type: none"> 5 mg QD: At least 2 weeks 10 mg QD: At least 4 weeks 20 mg QD: At least 4 weeks 40 mg QD: At least 4 weeks 60 mg QD: Max recommended dosage Doses should be escalated gradually based on acceptable safety and tolerability. Transaminases should be measured prior to any increase in dose	60 mg/day

Indication	Dosing Regimen	Maximum Dose
	<p>Modify dosing for patients taking concomitant cytochrome P450 (CYP) 3A4 inhibitors, renal impairment, or baseline hepatic impairment.</p> <p>Dose adjustments are also required for patients who develop transaminase values at least 3x ULN during Juxtapid treatment.</p>	

VI. Product Availability

Capsules: 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 60 mg

VII. References

1. Juxtapid Prescribing Information. Cambridge, MA: Aegerion Pharmaceuticals, Inc.; December 2019. Available at: <http://www.juxtapidpro.com/prescribing-information>. Accessed November 2, 2020.
2. Grundy SM, Stone NJ, Bailey AL, et al. 2018 ACC/AHA/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2018;Nov 10:[Epub ahead of print].
3. Jacobson TA, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 – full report. *Journal of Clinical Lipidology*. March-April 2015; 9(2): 129-169. <http://dx.doi.org/10.1016/j.jacl.2015.02.003>
4. Goldber AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *Journal of Clinical Lipidology*. June 2011; 5(3S): 1-15.
5. Fitchett DH, Hegele RA, Verma S. Statin intolerance. *Circulation* 2015;131:e389-391. <https://doi.org/10.1161/CIRCULATIONAHA.114.013189>.
6. Lloyd-Jones DM, Morris PB, Minissian MB, et al. 2017 Focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk. *J Am Coll Cardiol* 2017; 70(14):1785-1822. <http://dx.doi.org/10.1016/j.jacc.2017.07.745>.
7. Manpuya WM, Cho L, Frid D, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. *American Heart Journal* 2013; 166(3):597-603.
8. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings. *Ann of Intern Med* 2013; 158(7):526-534.
9. Backes JM, Ruisinger JF, Gibson CA, et al. Statin-associated muscle symptoms—managing the highly intolerant. *J Clin Lipidol*. 2017;11:24-33. Available at: <https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/05/03/10/43/statin-associated-muscle-symptoms>. Accessed November 2, 2020.
10. Thompson PD, Panza G, Zaleski A, et al. Statin-associated side effects. *JACC* 2016;67(20):2395-2410.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created	04.19.21	05.21

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2021 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.